Pyzina 500 mg (Pyrazinamide)

Product Overview

Pyzina 500 mg is a prescription pharmaceutical tablet that contains pyrazinamide, an anti‑tubercular agent classified as a first‑line drug for the treatment of active tuberculosis. Manufactured by Lupin Limited, a globally recognized generic drug company, Pyzina is supplied in a strip of ten tablets and is available in pack sizes of 30, 60, or 90 tablets to support continuous therapy. This product falls under the category of Life Saving Drugs, reflecting its critical role in national and international TB control programs. The medication is indicated for use in combination regimens with other antitubercular agents, such as isoniazid, rifampicin, and ethambutol, to improve cure rates and reduce the emergence of drug‑resistant Mycobacterium tuberculosis strains. Its availability in multiple pack sizes allows clinicians to tailor treatment length to individual patient needs while maintaining cost‑effectiveness for health systems.

What is Pyzina 500 mg?

Pyrazinamide is a synthetic analogue of nicotinamide that exhibits bactericidal activity against both replicating and non‑replicating populations of Mycobacterium tuberculosis. Unlike other first‑line agents, pyrazinamide is unique in that it is most effective at acidic pH, conditions commonly found within the granulomatous lesions of the lungs. The 500 mg strength of Pyzina delivers a dose that has been extensively studied in clinical trials and approved by regulatory authorities for inclusion in standard six‑month TB therapy. The tablet formulation is film‑coated to protect the active ingredient from gastric degradation, ensuring consistent absorption in the upper gastrointestinal tract. As a generic product, Pyzina contains the same active ingredient and bioavailability as the reference brand, offering patients an affordable yet therapeutically equivalent option.

Uses and Benefits

Pyrazinamide, the active moiety in Pyzina 500 mg, serves two primary purposes in TB therapy. First, it acts as a bactericidal component that rapidly reduces the bacterial load during the intensive phase of treatment, thereby shortening the time required to achieve sputum conversion. Second, its activity against dormant bacilli helps prevent relapse by targeting organisms that persist in a low‑oxygen environment. Clinical studies have demonstrated that inclusion of pyrazinamide in a regimen can increase the rate of smear‑negative conversion by up to 30 % compared with regimens that omit this agent. Additionally, the drug’s relatively low cost and stable shelf‑life make it suitable for large‑scale public health initiatives. Patients benefit from a simplified dosing schedule—typically once daily—supporting adherence and reducing the burden on directly observed therapy programs.

How It Works

The mechanism of action of pyrazinamide involves intracellular conversion to pyrazinoic acid by hepatic amidases. This metabolite interferes with fatty acid synthesis and disrupts the proton motive force across the mycobacterial cell membrane, leading to energy depletion and bacterial death. Importantly, pyrazinamide is most potent under acidic conditions, which are prevalent in the granulomas where M. tuberculosis resides. This property enables the drug to act on persistant bacilli that are otherwise tolerant to other antimicrobials. Pharmacokinetic studies show that peak plasma concentrations occur within two to three hours after oral administration, with a half‑life of approximately two hours. The drug is primarily metabolized in the liver and excreted renally, making hepatic function a key consideration in dose adjustment and safety monitoring. FDA guidelines endorse this mechanism as part of combination therapy for TB.

Dosage Guidelines

Standard adult dosing for Pyzina 500 mg consists of one tablet administered orally once daily, usually in combination with isoniazid, rifampicin, and ethambutol during the first two months of therapy, followed by a continuation phase of isoniazid and rifampicin alone. The exact duration and composition of the regimen should be individualized by a qualified healthcare professional based on patient‑specific factors such as disease severity, resistance patterns, and co‑existing medical conditions. For pediatric patients, dosing is weight‑based and must be prescribed accordingly. It is essential that patients complete the full course of treatment, even if symptoms improve early, to prevent the development of drug‑resistant TB. Missed doses should be taken as soon as remembered unless it is near the time of the next scheduled dose; in such cases, the missed dose should be skipped and regular dosing resumed. FDA recommends monitoring liver enzymes at baseline and periodically during therapy.

Side Effects

Like all medications, Pyzina 500 mg may cause adverse effects. The most frequently reported side effects include gastrointestinal disturbances such as nausea, vomiting, and loss of appetite, as well as skin rash or itching. Hepatotoxicity is a more serious concern; elevated liver enzymes can occur in up to 10 % of patients, and in rare instances, acute liver injury may develop. Patients should be advised to report persistent abdominal pain, dark urine, or jaundice promptly. Neurological symptoms such as peripheral neuropathy are uncommon but have been documented, particularly in individuals with pre‑existing liver disease. PubMed provides detailed pharmacokinetic data supporting these observations.

Warnings and Precautions

Prior to initiating treatment with Pyzina 500 mg, clinicians should assess hepatic function through baseline serum transaminase tests, especially in patients with a history of liver disease, alcohol use disorder, or concurrent hepatotoxic medications. The drug is contraindicated in individuals with known hypersensitivity to pyrazinamide or any component of the formulation. Pregnant and breastfeeding women should only use Pyzina when the potential benefit outweighs the risk, and dosing should be closely supervised. Drug interactions may occur with antiretrovirals, certain antitubercular agents, and medications that induce hepatic enzymes, potentially altering pyrazinamide levels. Patients should be counseled to avoid excessive alcohol consumption and to report any signs of jaundice or unexplained fatigue immediately. International standards from the World Health Organization emphasize these precautions. Complete disclosure of all current medications to a healthcare provider is essential to mitigate interaction risks.

Frequently Asked Questions

1. What is the recommended duration of Pyzina 500 mg therapy? The typical intensive phase lasts two months, after which patients may continue a maintenance phase that does not include pyrazinamide, but the exact length is determined by the prescribing clinician based on treatment response.
2. Can Pyzina 500 mg be taken with food? Yes, the tablet should be taken with a full glass of water and may be consumed with or without food; however, taking it with a meal can help reduce gastrointestinal upset.
3. Is Pyzina 500 mg safe for patients with HIV? Clinical data support the use of pyrazinamide in HIV‑co‑infected patients when used as part of a standard TB regimen, but close monitoring of liver enzymes is advised due to the higher prevalence of hepatotoxicity in this population.
4. How should the medication be stored? Pyzina 500 mg tablets should be kept in their original packaging at room temperature, protected from moisture and heat, and kept out of reach of children.
5. What should I do if I miss a dose? If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose; in that case, the missed dose should be skipped and the regular dosing schedule resumed.

Related Products

• R-Cinex 600 Mg (Isoniazid/Rifampicin)
• Ethambutol 200mg (Generic)
• Pyrazinamide 500 mg (Generic)
• Rofaday 500 mcg Tablet (Roflumilast)
• Nizonide (Nitazoxanide)
• Lupimeb 100 mg (Mebendazole)
• Nizonide 500 mg (Nitazoxanide)
• Nizonide DT 200mg (Nitazoxanide)
• Flugesic 100mg (Flupirtine)
• Abel 40 mg (Azilsartan Medoxomil)
• Cetil (Cefuroxime)
• Cetil 250mg (Cefuroxime)